The NIH is airing a live webcast and the event can be viewed live at: http://videocast.nih.gov/
Air date: Tuesday, February 22, 2011, 4:00:00 PM EST
Description: This event will include the presentation of patients, pathology, diagnosis and therapy context of major disease problems and current research. The course is designed to help bridge the gap between advances in biology and their application to major human diseases. Each session includes clinical and basic science components presented by NIH staff and invitees. These seminar series are primarily directed toward PhD students, clinicians and program managers. All students, fellows and staff are welcome, as well.
For more information, visit http://www1.od.nih.gov/oir/DemystifyingMed
Author: Shyh-Ching Lo (FDA), Fred Gill (NIDDK) and Harvey Alter (NIDDK)
Runtime: 120 minutes
Maybe this time we can get the straight talk without the interference and insinuations of smoke screeners and denialists like Dr. Stoye and others of his ilk we suffered at the Blood Products production.
Still no new info on this as of 2/15/2011.
Here's the NIH profile of Dr. Gill:
After receiving his medical degree from Northwestern University Medical School, Dr. Gill trained in internal medicine as an intern and resident at New York University-Bellevue Hospital followed by research training as a research associate of the National Institute of Allergy and Infectious Diseases (NIAID). He completed his clinical training as a medical resident and infectious disease fellow at Cornell-New York Hospital. Dr. Gill is an elected fellow of the American College of Physicians and the Infectious Diseases Society of America.
After many years of private practice in Bethesda, Maryland, Dr. Gill initiated the Internal Medicine Consultation Service for the Clinical Center in 1998. His practice in the Bethesda community combined primary care in internal medicine and consultation in infectious diseases. He served as chief of the Division of Infectious Diseases, Rheumatology and Allergy and chair of the Infection Control Committee at Suburban Hospital and as attending physician on the Consultant Service of NIAID’s Laboratory of Clinical Investigation. During this time, he participated as a co-investigator on research projects in the NIAID, the CC Clinical Pathology Department (now the Department of Laboratory Medicine), and the National Cancer Institute.
Dr. Gill led the development of the AIDS clinic for the Montgomery County Health Department and has chaired the AIDS Committee of the Medical and Chirugical Faculty of Maryland. He has served on many committees, including the Maryland Governor’s Advisory Council on AIDS, NIAID’s Advisory Council for Lyme Disease and Suburban Hospital’s Board of Trustees.
At NIH, besides heading the internal medicine consult service, Dr. Gill is chair of the CC Ethics Committee, principal coordinator for clinical education for the NIH Clinical Research Training Program, and an attending physician for NIAID’s Infectious Disease Consultation Clinic. He is a co-investigator on protocols of the National Human Genome Research Institute, National Eye Institute and NIAID. and served as the medical monitor for a National Human Genome Research Institute study. He is a member of data and safety monitoring boards for other institutes and of several CC and NIH committees.
And Dr Alter:
Dr. Harvey Alter earned his medical degree at the University of Rochester Medical School, and trained in internal medicine at Strong Memorial Hospital and at the University Hospitals of Seattle. In 1961, he came to the National Institutes of Health as a clinical associate. He then spent several years with Georgetown University, returning to NIH in 1969 to join the Clinical Center's Department of Transfusion Medicine as a senior investigator becoming Chief of the Clinical Studies and Associate Director of Research in the Department of Transfusion Medicine at the NIH Clinical Center.
Dr. Alter is also a clinical professor at Georgetown University.
Dr. Alter co-discovered the Australia antigen, a key to detecting hepatitis B virus. Later, Dr. Alter spearheaded a project at the Clinical Center that created a storehouse of blood samples used to uncover the causes and reduce the risk of transfusion-associated hepatitis. He was principal investigator on studies that identified non-A, non-B hepatitis, now called hepatitis C. His work was instrumental in providing the scientific basis for instituting blood donor screening programs that have decreased the incidence of transfusion-transmitted hepatitis to near zero.
In 2000, Dr. Alter was awarded the prestigious Clinical Lasker Award and in 2002, he became the first Clinical Center scientist elected to the National Academy of Sciences (NAS) and in that same year was elected to the Institute of Medicine. Only a small number of scientists nationally are elected to both these scientific societies.